THE COMMUNITY ONCOLOGY ALLIANCE announced that nine practices received accreditation as oncology medical homes through a pilot program by the Commission on Cancer.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
